A 'game-changing' British drug can halve the risk of dying from lung , research has shown.The ground-breaking trial found patients who received osimertinib after surgery were 51 per cent more likely to be alive five years later than those given a dummy pill.The daily tablets target non-small-cell lung cancer (NSCLC) tumours among people who have a specific genetic mutation which means they have stopped responding to earlier treatments.
Load More
Load More